Rhianna Laker is a Scientist in Research and Early Development in the Cardiovascular, Renal and Metabolism department at AstraZeneca. Her work focuses on identifying new drug targets for obesity, type 2 diabetes and non-alcoholic steatohepatitis and developing these drugs in preclinical models. Rhianna started her career at the University of Adelaide (Australia) with a bachelor of Biomedical science before moving to the University of Melbourne for her PhD in Physiology. She then moved to the US where she undertook postdoctoral training at the University of Virginia followed by additional training in Copenhagen at the Novo Nordisk Foundation Center for Basic Metabolic Research. Rhianna has been widely recognized for her contributions to science including a Research Recognition Award from the American Physiological Society and invited presentations at international conferences. In her spare time Rhianna enjoys sports, cooking and travel.
